Company intelligence / Profile preview

Evolutionary Biologics

New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Company develops regenerative biologic products including MSC-derived exosomes and tissue-based products for aesthetics, orthopedics, and wellness; products marketed as FDA compliant but FDA issued warning in December 2024 stating they are unapproved new drugs and unlicensed biologics.[6]

Therapeutic areas: OtherNeurologyDermatologyRheumatologyMen's Health
Modalities: Exosome-based therapyCell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Evolutionary Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evolutionary Biologics.

Explore the full profile